| Literature DB >> 30048473 |
Pedro Henrique Scheidt Figueiredo1,2, Márcia Maria Oliveira Lima2, Henrique Silveira Costa3, Jeanne Brenda Martins1, Olga Dumont Flecha4, Patrícia Furtado Gonçalves4, Frederico Lopes Alves5,6, Vanessa Gomes Brandão Rodrigues5,6, Emílio Henrique Barroso Maciel5,6, Vanessa Amaral Mendonça1,2, Ana Cristina Rodrigues Lacerda1,2, Érica Leandro Marciano Vieira3, Antônio Lúcio Teixeira3, Fabrício de Paula5, Cláudio Heitor Balthazar1,2.
Abstract
OBJECTIVE: Evaluate and compare the isolated and combined effects of Inspiratory Muscle Training (IMT) and Aerobic Training (AT) on respiratory and functional parameters, inflamatory biomarkers, redox status and health-related quality of life (HRQoL) in hemodialysis patients.Entities:
Mesh:
Substances:
Year: 2018 PMID: 30048473 PMCID: PMC6061993 DOI: 10.1371/journal.pone.0200727
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Fig 1Flow chart.
IMT: inspiratory muscle training; AT: aerobic training; CT: combined training.
Characteristics of the sample according to treatment allocation.
| IMT (N = 11) | AT (N = 13) | CT (N = 13) | p | |
|---|---|---|---|---|
| 7 (63.6) | 10 (76.9) | 9 (69.2) | 0.77 | |
| 4 (36.4) | 3 (23.1) | 4 (30.8) | ||
| 5 (45.5) | 6 (46.1) | 5 (38.4) | 0.64 | |
| 5 (45.5) | 4 (30.8) | 4 (30.8) | ||
| 1 (9.0) | 3 (23.1) | 4 (30.8) | ||
| 52.8 (43.1–62.5) | 49.5 (41.6–57.3) | 45.2 (34.8–55.5) | 0.46 | |
| 67.7 (54.9–80.5) | 69.1 (57.5–80.8) | 64.5 (52.9–76.2) | 0.82 | |
| 25.1 (21.1–29.2) | 25.2 (21.5–28.8) | 24.2 (20.9–27.2) | 0.85 | |
| 86.2 (73.4–98.9) | 87.9 (77.4–98.4) | 84.5 (73.9–95.2) | 0.89 | |
| 4 (36.4) | 3 (23.1) | 6 (46.1) | ||
| 2 (18.2) | 3 (23.1) | 3 (23.1) | ||
| 2 (18.2) | 1 (7.7) | 1(7.7) | ||
| 0 | 1 (7.7) | 0 | ||
| 3 (27.2) | 5 (38.4) | 3 (23.1) | ||
| 2 (18.2) | 1 (7.7) | 3 (23.1) | 0.56 | |
| 0 | 0 | 0 | ||
| 2 (18.2) | 2 (15.4) | 3 (23.1) | 0.88 | |
| 2 (18.2) | 2 (15.4) | 3 (23.1) | 0.88 | |
| 7 (63.6) | 7 (53.9) | 8 (61.5) | 0.80 | |
| 2 (18.2) | 5 (38.4) | 3 (23.1) | ||
| 2 (18.2) | 1(7.7) | 2 (15.4) | ||
| 4.4 (1.4–7.5) | 3.0 (0.5–6.4) | 4.9 (2.7–7.1) | 0.30 | |
| 1.7 (1.4–1.7) | 1.6 (1.4–1.7) | 1.5 (1.3–1.7) | 0.74 | |
| 70.5 (66.6–74.4) | 72.4 (68.6–76.2) | 71.7 (67.2–76.1) | 0.70 | |
| 10.9 (9.8–11.8) | 10.3 (9.4–11.2) | 10.9 (10.3–11.5) | 0.52 | |
| 34.4 (31.2–37.5) | 32.1 (29.6–34.6) | 33.8 (31.8–35.9) | 0.37 | |
| 3.7 (3.5–3.9) | 3.8 (3.6–4.0) | 3.9 (3.7–4.0) | 0.43 | |
| 3(27.2) | 2 (15.4) | 4 (30.8) | 0.81 | |
| 3(27.2) | 6 (46.2) | 5 (38.4) | ||
| 5(45.6) | 5 (38.4) | 4 (30.8) |
Data represented as mean (IC95%) or n (%). IMT: inspiratory muscle training group; AT: aerobic training group; CT: combined training group; BMI: body mass index; ESRD: End-Stage Kidney Disease; Kt/V:dialysis efficiency; Hb: hemoglobin.
Fig 2Effects of the interventions in primary outcomes.
A: inspiratory muscle strength; B: functional capacity; C: lower limb strength; MIP: máximal inspiratory pressure; ISWT: incremental shuttle walk test: IMT: inspiratory muscle training; AT: aerobic training; CT: combined training; ES: effect size; ■ Baseline; 8-week; 16-week. Baseline to 8-week: control period; 8-week to 16-week: intervention period. a: p<0.05 to baseline; b: p<0.05 to 8-week.
Effects of the interventions on anthropometric/physical parameter.
| Varibles | IMT (n = 10) | AT (n = 10) | CT (n = 11) | Within- group | Between-group | Interaction |
|---|---|---|---|---|---|---|
| p | p | p | ||||
| 0.201 | 0.713 | 0.451 | ||||
| Baseline | 70.0 (53.6–82.3) | 71.9 (58.6–85.2) | 64.6 (50.6–78.6) | |||
| 8-week | 68.7 (54.3–83.0) | 71.7 (59.0–84.3) | 65.2 (51.6–78.8) | |||
| 16-week | 68.5 (54.1–82.9) | 72.2 (59.6–84.8) | 64.9 (51.5–78.3) | |||
| 0.628 | 0.905 | 0.451 | ||||
| Baseline | 25.2 (20.7–29.6) | 25.8 (21.2–30.5) | 24.2 (20.6–27.8) | |||
| 8-week | 25.4 (21.0–29.8) | 26.2 (22.2–30.3) | 24.4 (20.9–27.9) | |||
| 16-week | 25.3 (20.9–29.8) | 26.4 (22.3–30.4) | 24.3 (20.9–27.8) | |||
| 0.090 | 0.744 | 0.181 | ||||
| Baseline | 85.1 (71.0–99.2) | 89.5 (77.2–101.7) | 83.4 (71.8–94.9) | |||
| 8-week | 85.9 (71.3–100.4) | 90.3 (77.8–102.8) | 83.6 (72.7–94.4) | |||
| 16-week | 86.1 (71.9–100.3) | 87.4 (74.6–100.2) | 82.3 (72.1–92.4) | |||
| 0.168 | 0.501 | 0.944 | ||||
| Baseline | 16.7 (12.8–20.5) | 18.6 (13.6–23.3) | 15.4 (8.5–22.3) | |||
| 8-week | 16.8 (12.9–20.6) | 18.7 (8.7–22.3) | 15.5 (8.7–22.3) | |||
| 16-week | 16.7 (12.8–20.6) | 18.8 (13.9–23.6) | 15.5 (8.7–22.4) |
Data represented as mean (IC95%). IMT: inspiratory muscle training group; AT: aerobic training group; CT: combined training group; BMI: body mass index; Baseline to 8-week: control period; 8-week to 16-week: intervention period.
Effects of the interventions on redox status parameters.
| Varibles | IMT | AT | CT | Within-group | Between-group | Interaction |
|---|---|---|---|---|---|---|
| p | p | p | ||||
| 0.58 | 0.63 | 0.75 | ||||
| Baseline | 27.3 (13.1–41.6) | 16.0 (12.1–19.9) | 24.1 (8.1–40.1) | |||
| 8-week | 22.2 (12.7–31.8) | 14.3 (8.06–20.6) | 25.1 (15.4–34.9) | |||
| 16-week | 22.3 (13.8–30.7) | 17.3 (13.4–21.2) | 24.4 (14.5–34.3) | |||
| 0.62 | 0.37 | 0.88 | ||||
| Baseline | 36.7 (31.2–42.2) | 26.5 (19.2–33.8) | 34.9 (24.1–48.7) | |||
| 8-week | 39.7 (29.2–50.2) | 29.5 (18.7–40.3) | 40.5 (28.9–52.1) | |||
| 16-week | 42.2 (31.4–52.9) | 25.8 (18.4–33.1) | 38.2 (29.1–47.2) | |||
| 0.37 | 0.45 | 0.37 | ||||
| Baseline | 0.3 (0.1–0.4) | 0.2 (0.1–0.2) | 0.2 (0.1–0.3) | |||
| 8-week | 0.2 (0.1–0.4) | 0.2 (0.1–0.2) | 0.2 (0.1–0.3) | |||
| 16-week | 0.1 (0.0–0.2) | 0.2 (0.1–0.2) | 0.2 (0.1–0.4) | |||
| 0.57 | 0.18 | 0.32 | ||||
| Baseline | 49.2 (29.7–68.6) | 41.5 (34.6–48.3) | 36.8 (31.0–42.7) | |||
| 8-week | 46.8 (29.9–63.6) | 44.7 (35.1–54.4) | 38.2 (34.3–42.0) | |||
| 16-week | 35.9 (27.2–44.6) | 43.1 (36.0–50.1) | 36.6 (24.4–46.8) |
Data represented as mean (IC95%). IMT: inspiratory muscle training group; AT: aerobic training group; CT: combined training group; SOD: superoxide dismutase; TBARS: thiobarbituric-acid-reactive substances; FRAP: ferric reducing antioxidant power: Baseline to 8-week: control period; 8-week to 16-week: intervention period.
Fig 3Effects of the interventions on plasma sTNFR1, sTNFR2 and IL-6 levels.
A: plasma sTNFR1 levels; B: plasma sTNFR2 levels; C: plasma IL-6 levels; sTNFR1 and 2: soluble receptors 1 and 2, respectively, of the tumor necrosis alpha factor; IL-6: interleukin 6; IMT: inspiratory muscle training group; AT: aerobic training group; CT: combined training group; ES: effect size; ■ Baseline; 8-week; 16-week. Baseline to 8-week: control period; 8-week to 16-week: intervention period. a: p<0.05 to baseline; b: p<0.05 to 8-week.
Fig 4Effects of the interventions on plasma adipokines levels.
A: plasma adiponectin levels; B: plasma resistin levels; C: plasma leptin levels; IMT: inspiratory muscle training group; AT: aerobic training group; CT: combined training group; ES: effect size; ■ Baseline; 8-week; 16-week. Baseline to 8-week: control period; 8-week to 16-week: intervention period. a: p<0.05 to baseline; b: p<0.05 to 8-week.